Effectiveness of zonisamide in childhood refractory epilepsy

Basit Öğe Kaydı
dc.authoridASLAN, MAHMUT/0000-0002-5355-8994
dc.authoridGUNGOR, SERDAL/0000-0003-3875-6770
dc.contributor.authorAslan, Mahmut
dc.contributor.authorGungor, Serdal
dc.date.accessioned2024-08-04T20:51:37Z
dc.date.available2024-08-04T20:51:37Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction Zonisamide (ZNS) is a new generation antiepileptic drug (AED) used in refractory epilepsy. This study assessed the effectiveness and reliability of ZNS in childhood refractory epilepsy. Method Sixty-eight epilepsy patients who were followed up in the paediatric neurology clinic, between 2013 and 2019, and in whom add-on therapy ZNS had been added as their seizures had continued despite multiple drugs being used, were included in this retrospective study. Their demographic findings, seizure aetiology, pre-treatment and post-treatment electroencephalography findings, treatment responses and any side effects of the drugs given were assessed in these patients. Results There were 46 (67.6%) patients in the refractory generalized epilepsy (RGE) group using multiple AEDs and 22 (32.35%) patients in the refractory focal epilepsy (RFE) group. Of these patients, 12 (17.65%) were being followed up for idiopathic epilepsy and 8 (11.76%) were being followed up for epilepsy of unknown aetiology. Twenty-two (32.36%) patients were followed up for structural abnormality, 8 patients (11.77%) were followed up for genetic disease, 4 patients (5.88%) were followed up for infectious sequel, 14 patients (20.59%) were followed up for metabolic reasons. In the RGE group, a more than 50% reduction was found in the seizures of 26 (56.5%) patients, while the seizures of 7 (15.2%) patients were found to have terminated completely. In the RFE group, a more than 50% reduction was found in the seizures of 19 (86.4%) patients, while the seizures of 2 (9.1%) patients were found to have terminated completely. The termination or a more than 50% reduction in seizures in 4 of the 6 patients followed up for a diagnosis of tuberous sclerosis complex (TSC) was significant. Conclusion ZNS is an effective and reliable option as an add-on therapy in paediatric refractory epilepsy, especially in focal epilepsy. It can also be considered for treatment in TSC patients.en_US
dc.identifier.doi10.1007/s00381-022-05458-y
dc.identifier.endpage976en_US
dc.identifier.issn0256-7040
dc.identifier.issn1433-0350
dc.identifier.issue5en_US
dc.identifier.pmid35083515en_US
dc.identifier.scopus2-s2.0-85123589848en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage971en_US
dc.identifier.urihttps://doi.org/10.1007/s00381-022-05458-y
dc.identifier.urihttps://hdl.handle.net/11616/100445
dc.identifier.volume38en_US
dc.identifier.wosWOS:000749160700002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofChilds Nervous Systemen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectZonisamideen_US
dc.subjectRefractory epilepsyen_US
dc.subjectEEGen_US
dc.subjectChildrenen_US
dc.titleEffectiveness of zonisamide in childhood refractory epilepsyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu